Iron- and manganese-catalyzed autoxidation of dopamine in the presence of L-cysteine: Possible insights into iron- and manganese-mediated dopaminergic neurotoxicity

Chemical Research in Toxicology

Volumn 11, Issue 7, 1998, Pages 824-837

  Shen, Xue Ming ^a   Dryhurst, Glenn ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; IRON; MANGANESE;

ARTICLE; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; MITOCHONDRIAL RESPIRATION; NERVE CELL DEGENERATION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; PARKINSONISM;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYSTEINE; DOPAMINE; ELECTROCHEMISTRY; IRON; MAGNETIC RESONANCE SPECTROSCOPY; MANGANESE; OXIDATION-REDUCTION; PARKINSON DISEASE; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 0031828219     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx980036t     Document Type: Article

References (64)

1. Jenner, P., and Olanow, C. W. (1996) Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47, 161-170.
2. Sofic, E., Riederer, P., Heisen, H., Bechmann, H., Reynolds, G. P., Habenstreit, G., and Youdim, M. B. H. (1988) Increases of iron (III) and total iron in postmortem substantia nigra in parkinsonian brains. J. Neural Transm. 74, 199-205.
3. Riederer, P., Sofie, E., Rausch, W.-D., Schmidt, B., Reynolds, G. P., Jellinger, K., and Youdim, M. B. H. (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains, J. Neurochem. 52, 515-520.
4. Dexter, D. T., Carayon, A., Vidailhet, M., Ruberg, M., Agid, F., Agid, Y., Lees, A., Wells, F. R., and Marsden, C. D. (1990) Decreased ferritin levels in brain in Parkinson's disease. J. Neurochem. 55, 16-20.
5. Jellinger, K., Kienzl, E., Rumpelmair, G., Riederer, P., Stachelberger, H., Ben-Shachar, D., and Youdim, M. B. H. (1992) Ironmelanin complex in substantia nigra of parkinsonian brains: an X-ray microanalysis. J. Neurochem. 59, 1168-1171.
6. Pilas, B., Sarna, T., Kalyanarman, B., and Swatz, H. M. (1988) The effect of melanin on iron-associated decomposition of hydrogen peroxide. Free Radical Biol. Med. 4, 285-293.
7. Ben-Shachar, D., Riederer, P., and Youdim, M. B. H. (1991) Ironmelanin interaction and lipid peroxidatiun: implications for Parkinson's disease. J. Neurochem. 57, 1609-1614.
8. Youdim, M. B. H., Ben-Shachar, D., and Riederer, P. (1989) Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration. Acta Neurol. Scand. 126, 47-55.
9. Ben-Shachar, D., and Youdim, M. B. H. (1991) Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats. J. Neurochem. 57, 2133-2135.
10. Sengstock, G. J., Olanow, C. W, Menzies, R., Dunn, A. J., and Arendash, G. W. (1993) Infusion of iron into the rat substantia nigra: nigral pathology and dose-dependent loss of striatal dopaminergic markers. J. Neurosci. Res. 35, 76-82.
11. Graham, D. G. (1984) Catecholamine toxicity: A proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson's disease. Neurotoxicology 5, 83-96.
12. Barbeau, A. (1984) Manganese and extrapyramidal disorders Neurotoxicology 5, 13-36.
13. Donaldson, J., McGregor, D., and LaBella, F. (1982) Manganese neurotoxicity: a model for free radical mediated neurodegeneration? Can. J. Physiol. Pharmacol. 60, 1398-1405.
14. Lloyd, R. V. (1995) Mechanism of the manganese-catalyzed autoxidation of dopamine. Chem. Res. Toxicol. 8, 111-116.
15. Archibald, F. S., and Tyree, C. (1987) Manganese poisoning and the attack of trivalent manganese on catecholamines. Arch. Biochem. Biophys. 256, 638-650.
16. Graham, D. G. (1978) Oxidation pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14, 633-643.
17. Fornstedt, B., Brun, A., Rosengren, E., and Carlsson, A. (1989) The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra. J. Neural Transm. P. D. Dementia Sect. 1, 279-295.
18. Mann, D. M. A., and Yates, P. O. (1983) Possible role of neuromelanin in the pathogenesis of Parkinson's disease. Mech. Aging Dev. 21, 193-203.
19. Hirsch, E. C., Graybiel, A. M., and Agid, Y. (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334, 345-348.
20. Kastner, A., Hirsch, E. C., Lejeune, O., Javoy-Agid, F., Rascol, O., and Agid, Y. (1992) Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J. Neurochem. 59, 1080-1089.
21. Chandra, S. V., and Shukla, G. S. (1981) Concentration of striatal catecholamines in rats given manganese chloride through drinking water. J. Neurochem. 36, 683-687.
22. Liccione, J. J., and Maines, M. D. (1988) Selective vulnerability of glutathione metabolism and cellular defense mechanisms in rat striatum to manganese. J. Pharmacol. Exp. Ther. 247, 156-161.
23. Sian, J., Dexter, D. T., Lees, A. J., Daniel, S., Agid, Y., Javoy-Agid, F., Jenner, P., and Marsden, C. D. (1994) Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting the basal ganglia Ann. Neurol. 36, 348-355.
24. Dexter, D. T., Sian, J., Rose, S., Hindmarsh, G., Mann, V. M., Cooper, J. M., Wells, F. R., Daniel, S. E., Lees, A. J., Schapira, A. H. V., Jenner, P., and Marsden, C. D. (1994) Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann. Neurol. 35, 38-44.
25. Sian, J., Dexter, D. T., Lees, A. J., Daniel, S., Jenner, P., and Marsden, C. D. (1994) Glutathione-related enzymes in brain in Parkinson's disease. Ann. Neurol. 36, 356-361.
26. Perry, T. L., Godin, D. A., and Hansen, S. (1982) Parkinson's disease: A disorder due to nigral glutathione deficiency? Neurosi. Lett. 33, 305-310.
27. Toffa, S., Kunikowska, G. M., Zeng, B.-Y., Jenner, P., and Marsden, C. D. (1997) Glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration. J. Neural Transm. 104, 67-75.
28. Slivka, A., Mytilineou, C., and Cohen, G. (1987) Histochemical evaluation of glutathione in brain. Brain Res 409, 275-284.
29. Pearce, R. K. B., Owen, A., Daniel, S., Jenner, P., and Marsden, C. D. (1997) Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J. Neural Transm. 104, 661-677.
30. Zhang, F., and Dryhurst, G. (1994) Effects of L-cysteine on the oxidation chemistry of dopamine: reaction pathways of potential relevance to idiopathic Parkinson's disease. J. Med. Chem. 37, 1084-1098.
31. Shen, X.-M., and Dryhurst, G. (1996) Further insights into the influence of L-cysteine on the oxidation chemistry of dopamine: reaction pathways of potential relevance to Parkinson's disease. Chem. Res. Toxicol. 9, 751-763.
32. Dryhurst, G. (1997) Glutathione, cysteine, and the neuromelanin pathway: potential roles in the pathogenesis of Parkinson's disease - a new hypothesis. In Glutathione in the Nervous System (Shaw, C. A., Ed.) pp 305-342, Taylor and Francis, Washington, DC.
33. Li, H., and Dryhurst, G. (1997) Irreversible inhibition of mitochondrial complex I by 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy2H-1,4-benzothiazine-3-carboxylic acid (DHBT-1): a putative nigral endotoxin of relevance to Parkinson's disease. J. Neurochem. 69, 1530-1541.
34. 1 reductase (complex I) deficiency in Parkinson's disease. J. Neurochem. 55, 2142-2145.
35. Harris, Z. L., Takahashi, Y., Miyajima, H., Serizawa, M., MacGillivray, R. T. A., and Gitlin, J. D. (1995) Aceroplasminimia: molecular characterization of this disorder of iron metabolism. Proc. Natl. Acad. Sci. U.S.A. 92, 2539-2543.
36. Shen, X.-M., Zhang, F., and Dryhurst, G. (1997) Oxidation of dopamine in the presence of cysteine: characterization of new toxic products. Chem. Res. Toxicol. 10, 147-155.
37. Napolitano, A., Constantini, C., Crescenzi, O., and Prota, G. (1994) Characterization of 1,4-benzothiazine intermediates in the oxidative conversion of 5-S-cysteinyldopa to pheomelanins. Tetrahedron Lett. 35, 6365-6368.
38. Saez, G., Thornalley, P. J., Hill, H. A. O., Hems, R., and Bannister, J. V. (1982) The production of free radicals during the autoxidation of cysteine and their effect on isolated rat hepatocytes. Biochim. Biophys. Acta 719, 24-31.
39. Rowley, D. A., and Halliwell, B. (1982) Superoxide-dependent formation of hydroxyl radicals in the presence of thiol compounds. FEBS Lett. 138, 33-36.
40. 2. Int. J. Radiat. Phys. Chem. 2, 159-166.
41. Bielski, B. H. J., and Allen, A. O. (1977) Mechanism of the disproportionation of Superoxide radicals. J. Phys. Chem. 81, 1048-1050.
42. Adams, G. E., Armstrong, R. C., Charlesby, A., Michael, B. D., and Willson, R. L. (1969). Pulse radiolysis of sulphur compounds Part 3. Repair by hydrogen transfer of a macromolecule irradiated in aqueous solution. Trans. Faraday Soc. 65, 732-742.
43. Spencer, J. P. E., Jenner, P., and Halliwell, B. (1995) Superoxide-dependent depletion of reduced glutathione by L-DOPA and dopamine. Relevance to Parkinson's disease. NeuroReport 6, 1480-1484.
44. Ito, S., and Fujita, K. (1984) Oxygen-dependent conjugation of DOPA with cysteine catalysed by iron-EDTA complex. Biochem. Pharmacol. 33, 2193-2197.
45. Minotti, G., and Aust, S. D. (1992) Redox cycling of iron and lipid peroxidation. Lipids 27, 219-226.
46. Chedekel, M. R., Land, E. J., Thompson, A., and Truscott, T. G. (1984) Early steps in the free radical polymerisation of 3,4-dihydroxyphenylalanine (Dopa) into melanin. J. Chem. Soc., Chem. Commun. 1170-1172.
47. 2+) complex: a possible mechanism of nigrostriatal cell damage. Arch. Biochem. Biophys. 283, 334-341.
48. Napolitano, A., Memoli, S., Nappi, A. J., d'Ischia, M., and Prota, G. (1996) 5-S-Cysteinyldopa, a diffusable product of melanocyte activity, is an efficient inhibitor of hydroxylation/oxidation reactions induced by the Fenton system Biochim. Biophys. Acta 1291, 75-82.
49. Palumbo, A., d'Ischia, M., Misuraca, G., De Martino, L., and Prota, G. (1995) Iron- and peroxide-dependent conjugation of dopamine with cysteine: oxidative routes to the novel brain metabolite 5-S-cysteinyldopamine. Biochim. Biophys. Acta 1245, 255-261.
50. Constantini, C., Crescenzi, O., and Prota, G. (1990) New intermediates of phaeomelanogenesis in vitro beyond the 1,4-benzothiazine stage. Tetrahedron Lett. 46, 6831-6838
51. Chedekel, M. R., and Zeise, L. (1988) Sunlight, melanogenesis and radicals in the skin. Lipids 23, 587-591.
52. Archibald, F. S., and Tyree, C. (1987) Manganese poisoning and the attack of trivalent manganese on catecholamines. Arch. Biochem. Biophys. 256, 638-650.
53. Linert, W., Herlinger, E., Jameson, R. F., Kienzl, E., Jellinger, K., and Youdim, M. B. (1996) Dopamine, 6-hydroxydopamine, iron, and dioxygen - their mutual interactions and possible implication in the development of Parkinson's disease. Biochim. Biophys. Acta 1316, 160-168.
54. Pezzella, A., d'Ischia, M., Napolitano, A., Misuraca, G., and Prota, G. (1997) Iron-mediated generation of the neurotoxin 6-hydroxydopamine quinone by a reaction of fatty acid hydroperoxides with dopamine: a possible contributory mechanism for neuronal degeneration in Parkinson's disease. J. Med. Chem. 40, 2211-2216
55. Jellinger, K., Paulus, W., Grundke-Iqbal, I., Riederer, P., and Youdim, M. B. H. (1990) Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J. Neural Transm. 2, 327-340.
56. Jenner, P., Dexter, D. T., Sian, J., Schapira, A. H. V., and Marsden, C. D. (1992) Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. Ann. Neurol. 32, S82-S87.
57. Dexter, D. T., Holley, A. E., Flitter, W. D., Slator, T. F., Wells, F. R., Daniel, S. E., Less, A. J., Jenner, P., and Marsden, C. D. (1994) Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov. Disord. 9, 92-97.
58. Alam, Z. I., Daniel, S. E., Lees, A. J., Marsden, D. C., Jenner, P., and Halliwell, B. (1997) A generalized increase in protein carbonyls in the brain in Parkinson's but not in incidental Lewy body disease. J. Neurochem. 69, 1326-1329.
59. Li, H., Shen, X.-M., and Dryhurst, G. (1998) Brain mitochondria catalyze the oxidation of 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxylic acid (DHBT-1) to intermediates that irreversibly inhibit complex I and scavenges glutathione: potential relevance to the pathogenesis of Parkinson's disease. J. Neurochem., in press.
60. Gorell, J. M., Johnson, C. C., Rybicki, B. A., Peterson, E. L., Kortsha, G. X., Brown, G. G., and Richardson, R. J. (1997) Occupational exposures to metals as risk factors for Parkinson's disease. Neurology 48, 650-658.
61. Bonifati, M. G., Vanacore, N., and Fabrizio, E. (1994) Parkinsonism after chronic exposure to the fungicide maneb (manganese ethylene-bis-dithiocarbamate). Scand. J. Work Environ. Health 20, 301-305.
62. Rybicki, B. A., Johnson, C. C., Uman, J., and Gorell, J. M. (1993) Parkinson's disease mortality and the industrial use of heavy metals in Michigan. Mov. Disord. 1, 87-92.
63. Wang, J. D., Huang, C. C., Hwang, Y. H., Chiang, J. R., Lin, J. M., and Chen, J. S. (1989) Manganese-induced parkinsonism: an outbreak due to an unrepaired ventilation control system in a ferromanganese smelter. Br. J. Ind. Med. 46, 856-859.
64. Ross, M. H., Romrell, L. J., and Kaye, G. I. (1995) Histology. A Text and Atlas, Chapter 11, p 282, Williams and Wilkins, Baltimore, MD.